Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim
Daiichi Sankyo
Argus Health
US Department of Justice

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,474,770

« Back to Dashboard

Title: Oligosaccharides having anti-Xa activity, pharmaceutical compositions containing them and method of use
Abstract:Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a U.S.P. titer in a ratio of at least 30. They consist of chains constituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.
Inventor(s): Lormeau; Jean-Claude (Maromme la Maine, FR), Choay; Jean (Paris, FR), Petitou; Maurice (Paris, FR)
Assignee: Choay S.A. (Paris, FR)
Filing Date:Aug 22, 1983
Application Number:06/525,372
Claims:1. An oligosaccharide fraction of the heparin chain which oligosaccharide which has improved antithrombotic activity in vivo (as measured by the Yin-Wessler test) higher than that of heparin, which oligosaccharide fraction (1) comprises not more than 8 saccharide units, (2) of which one is an N-sulfate-D-glucosamine unit, (3) has anti-Xa activity (measured by the Yin-Wessler test) at least 10 times that of heparin, (4) specific affinity for AT III, (5) a ratio of Yin-Wessler titer to U.S.P. titer of at least 30 and (6) virtually no anticoagulant activity (as determined by the U.S.P. test) and, the biologically acceptable salts of said oligosaccharide.

2. A therapeutic antithrombotic composition which has antithrombotic activity (as measured by the Yin-Wessler test) higher than that of heparin which composition comprises a therapeutically acceptable carrier and in a therapeutically effective amount, an oligosaccharide of claim 1.

3. A therapeutic method for controlling thrombosis in a patient which comprises administering to said patient the therapeutic antithrombotic composition of claim 2 and controlling thrombosis.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.